Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series.

ABSTRACT:

Introduction

Persistent B cell depletion is a rare complication of rituximab treatment, and its clinical implications are unknown.

Methods

This retrospective case series included patients with glomerular and autoimmune diseases who developed persistent B cell depletion (< 5 CD19⁺CD20⁺ cells/μl persisting for > 2 years) after the last rituximab dose.

Results

Among 1519 patients who received rituximab, 2% (n = 30) had persistent B cell depletion. The frequencies of persistent B cell depletion were 2.5% (22 of 878), 2.4% (2 of 82), and 0.8% (1 of 114) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus (SLE) or lupus nephritis, and podocytopathies, respectively. The remaining patients ha

SUBMITTER: Efe O 

PROVIDER: S-EPMC12142800 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature